Melanoma, a type of skin cancer, poses a significant health concern globally. Advanced and metastatic stages of melanoma present particularly formidable challenges, often necessitating innovative treatment approaches to address their aggressive nature and high mortality rates.
Patients with ICI-resistant metastatic melanoma face limited treatment options. While investigational unengineered TIL (tumor-infiltrating lymphocyte) cell therapy has shown promise, systemic high-dose IL2 co-administration restricts patient eligibility and poses safety risks.
At AACR 2024, Obsidian Therapeutics presented positive data from a Phase I (NCT05470283) study of its tumor-infilt...
